Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meeting
May 01 2024 - 3:03PM
Business Wire
Vesigen Therapeutics, Inc., a biotechnology company developing a
novel non-viral delivery platform for gene editors, RNA, and
protein-based therapeutics, today announced that the Company will
be presenting two posters sharing new preclinical data from its
engineered ARMMs platform at the upcoming Association for Research
in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting will
be held in Seattle, Washington from May 5-9.
Vesigen’s technology comprises engineered forms of a class of
naturally existing vesicles to enable efficient functional delivery
of complex intracellular payloads, while overcoming challenges
observed with other modalities such as tissue specificity,
toxicity, and re-dosability.
Vesigen will present preclinical data demonstrating successful
biodistribution of its engineered ARMMs to non-human primate (NHP)
photoreceptors and retinal pigment epithelium. The Company will
also share new preclinical NHP data demonstrating functional
delivery of genome editors to the retina and supporting therapeutic
use of ARMMs in ocular diseases.
Details of the poster presentations are listed below. For more
information about the ARVO Annual Meeting, including registration
details, please visit https://www.arvo.org/annual-meeting/.
ARMMs as Non-viral Vehicles for the Delivery of Genome
Editors to Treat Stargardt Disease
- Poster Number: A0081
- Date: May 6 at 3:00pm EST
- Session: 245
- Location: Exhibit Hall
Biodistribution of ARMMs as Non-Viral Vehicles for
Therapeutic Payloads by Sub-Retinal Administration in Minipigs and
NHP
- Poster Number: B0291
- Date: May 8 at 2:15pm EST
- Session: 449
- Location: Exhibit Hall
About Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company developing a
novel, non-viral delivery technology for gene editing, RNA, and
protein-based therapeutics. Vesigen’s patented technology, ARMMs
(ARRDC1 Mediated Microvesicles), can precisely deliver a wide range
of payloads to a unique set of tissue and cell types. Vesigen has
demonstrated highly efficient in vitro and in vivo functional
delivery of a range of payloads across multiple cell types and is
committed to developing transformative medicines that address
current unmet medical needs. ARMMs were discovered and engineered
into a drug delivery system at the Harvard T.H. Chan School of
Public Health.
For additional information visit www.vesigen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501521043/en/
Investor and Media Contact: Adam Bero, Ph.D. Kendall
Investor Relations abero@kendallir.com